Silk-based microneedle transdermal immunization with EV71 vaccines elicits potent immune responses in mice
Journal Title: Journal of Vaccines & Immunization - Year 2016, Vol 4, Issue 1
Abstract
Hand, foot, and mouth disease (HFMD), caused by EV71 viral infection, has emerged as a serious public health concern in the Asia-Pacific region. The lack of effective treatment has led to a focus on controlling EV71 epidemics through development of vaccines. This study compares the potency of inactivated whole-virus EV71 vaccine with recombinant viral protein (rVP) subunit vaccine, administered by various immunization routes including intraperitoneal (IP), intradermal (ID), or using a microneedle (MN) patch. The MN patches, made of biocompatible silk proteins loaded with antigens and adjuvant, were applied directly to the skin. Both inactivated virus and rVPs vaccines generated substantial EV71 specific serum IgG, but only the former induced neutralizing antibody. Immunization with silk MN patches induced comparable neutralizing antibody titers to the IP and ID. These findings suggest that inactivated EV71 virus was superior to rVP subunit vaccine in stimulating neutralizing antibody and that with some fine-tuning; the silk-based MN patches are an effective and non-invasive delivery platform for EV71 and possibly for other immunogens.
Authors and Affiliations
Xu B, Raja WK, Lee S, Liu W, Diwan IM, Panilaitis BJ, Kaplan DL, Tzipori S
Keywords
Related Articles
- EP ID EP565995
- DOI 10.14312/2053-1273.2016-1
- Views 52
- Downloads 0
Routine immunization services in Africa: back to basics
National immunization programmes were created as a sequel to smallpox eradication when countries undertook mass immunization campaigns and other control measures to fight the disease. As smallpox came near to eradication...
Developing a vaccine for human rhinoviruses
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute...
Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardi...
From package to protection: how do we close global coverage gaps to optimize the impact of vaccination?
The success of every vaccination program is dependent upon reaching and sustaining the target coverage rates. Vaccination programs are currently facing coverage gaps where target coverages are never reached and may also...
Impact of strategies and activities for reducing morbidity and mortality of vaccine-preventable diseases in Oman: A status report
Immunization is the only child survival strategy which alone averts two to three million deaths each year. This has been possible because of high coverages achieved by many countries in the world. Still nearly 1.5 millio...